NasdaqGM - Delayed Quote USD

Barinthus Biotherapeutics plc (BRNS)

1.0300

-0.1100

(-9.65%)

At close: January 10 at 4:00:00 PM EST

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identifiedExtending the cash runway to the start of 2027 by reducing costs, including an approximate 65% reduction in workforce and expected closure of the U.K. site Future operations will be focused at the U.S. site in Germantown, Maryland OXFORD, United Kingdom and GERMANTOWN, Md., Jan. 10, 2025 (GLOBE NEWSWIRE)

GlobeNewswire 14 hours ago

BRNS
-9.65%
Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar

As the Dow Jones Industrial Average experiences a prolonged losing streak and investors closely watch Federal Reserve decisions, market participants are seeking opportunities that might weather such volatility. Penny stocks, though often seen as speculative, can still hold potential when they exhibit strong financial fundamentals. These smaller or newer companies may offer unique value propositions and growth prospects that could appeal to investors looking for under-the-radar opportunities...

Simply Wall St. 24 days ago

SPRU

EDSA

BRNS
-9.65%
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio’s CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company dev

GlobeNewswire last month

BRNS
-9.65%
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), today announced the most significant data so far from the ongoing Phase 2b HBV003 clinical trial. The data will be presented by Dr. Chun-Jen Liu as an oral presentation on November 18, 2024, at 17:30 PT at the Ame

GlobeNewswire last month

BRNS
-9.65%
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts assessed previously23% of participants receiving imdusiran, VTP-300 and low-dose nivolumab reached HBsAg loss by Week 48 WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensiv

GlobeNewswire last month

ABUS

BRNS
-9.65%
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

OXFORD, United Kingdom, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, provided an overview of business updates and announced financial results for the third quarter of 2024. “We continue our strong execution on our clinical trials, completing enrollment in the HBV003 trial of VTP-300 in chronic hepatitis B, and advancing VTP-1000 in cel

GlobeNewswire 2 months ago

BRNS
-9.65%
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

OXFORD, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, today announced that updated clinical data from its chronic hepatitis B program will be highlighted as a late breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024 being held November 15-19, 2024 in Sa

GlobeNewswire 2 months ago

BRNS
-9.65%
ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch

As major U.S. indexes experience a downturn, with large-cap stocks like Nvidia and Apple leading the decline and Treasury yields on the rise, investors are seeking alternative opportunities in different market segments. Penny stocks, often associated with smaller or emerging companies, offer a unique chance for growth at lower price points despite their vintage name. By focusing on those with strong financial foundations, these stocks can present potential value and stability amidst current...

Simply Wall St. 2 months ago

BRNS
-9.65%
TOUR

CDXC
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update for HBV003 anticipated in Q4 2024.Data update for PCA001 anticipated in H1 2025. OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, announced the completion of enrollmen

GlobeNewswire 3 months ago

BRNS
-9.65%
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer from celiac disease, for which no approved treatments currently exist.The first-in-human Phase 1 trial aims to evaluate the safety and tolerability in adults with celiac disease. OXFORD, United Kingdom, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company devel

GlobeNewswire 3 months ago

BRNS
-9.65%
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

OXFORD, United Kingdom, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, provided an overview of the Company’s progress and announced its financial results for the second quarter of 2024. “Following the positive VTP-300 Phase 2 data in hepatitis B virus (HBV) in the second quarter, we made the strategic decision to prioritize our HBV and celiac disease programs. These t

GlobeNewswire 5 months ago

BRNS
-9.65%
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

SAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Anne Phillips and Jennifer Jarrett, to the board of directors of the Company, effective August 1, 2024. “We are thrilled to welcome Anne and Jennifer to our boar

GlobeNewswire 5 months ago

BRNS
-9.65%
ZURA

ZURAW
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 5 months ago

BRNS
-9.65%
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized.The pipeline prioritization is expected to result in a reduction in workforce of approximately 25% and an estimated extension to the cash runway into the second quarter of 2026. OXFORD, United Kingdom, June 12, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announce

GlobeNewswire 6 months ago

BRNS
-9.65%
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation.In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24-weeks post-end of treatment (EOT

GlobeNewswire 7 months ago

BRNS
-9.65%
ABUS
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.OXFORD, United Kingdom, May 22, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (the Company), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide

GlobeNewswire 7 months ago

BRNS
-9.65%
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. “So far in 2024 we have continued to make strides across our programs. Notably, we r

GlobeNewswire 7 months ago

BRNS
-9.65%
Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)

Key Insights Barinthus Biotherapeutics will host its Annual General Meeting on 10th of May Salary of US$610.0k is part...

Simply Wall St. 8 months ago

BRNS
-9.65%
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseasesOXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today an

GlobeNewswire 8 months ago

BRNS
-9.65%
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events (AEs) or serious AEs (SAEs). Positive trends in clearance rate for both high-risk (hr)HPV (60%, Group 2) and cervical lesions (67%,Groups 2 and 5), were observed in the groups receiving the highest ChAdOx dose.Pooled data from the five different active dose groups demonstrated no statistically significant improvement in either hrHPV or cervical lesion clearance in compari

GlobeNewswire 8 months ago

BRNS
-9.65%

Performance Overview

Return	BRNS	MSCI WORLD
YTD	-6.36%	-1.09%
1-Year	-71.39%	+16.34%
3-Year	-91.04%	+16.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Barinthus Biotherapeutics plc (BRNS)

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Edesa Biotech And 2 Other Promising US Penny Stocks For Your Radar

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

ChromaDex Leads The Charge With 2 Other US Penny Stocks To Watch

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Performance Overview